AID Orchestrates MYC/E2F Target Gene Activation and Cell-of-Origin Transcriptional Programs in Diffuse Large B-cell Lymphoma
RNA-seq (gene expression) · human · 42 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Topic
- Diffuse large B-cell lymphomaThis series is part of our curated briefing on it.
- Samples
- 42 samples: 10 conditions, mostly in triplicateGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE308040_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1328619 and SRA study SRP620424. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 30 samples.
How we read this: 10 replicated groups read from 42 sample titles; they account for 30 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM9236222 HBL1_AID_cl.4 HBL1_AID_cl
- GSM9236223 HBL1_AID_cl.5 HBL1_AID_cl
- GSM9236224 HBL1_AID_cl.6 HBL1_AID_cl
- GSM9236225 HBL1_NT_cl.1 HBL1_NT_cl
- GSM9236226 HBL1_NT_cl.2 HBL1_NT_cl
- GSM9236227 HBL1_NT_cl.3 HBL1_NT_cl
- GSM9236228 TMD8_AID_cl.6 TMD8_AID_cl
- GSM9236229 TMD8_AID_cl.4 TMD8_AID_cl
- GSM9236230 TMD8_AID_cl.5 TMD8_AID_cl
- GSM9236231 TMD8_NT_cl.1 TMD8_NT_cl
- GSM9236232 TMD8_NT_cl.2 TMD8_NT_cl
- GSM9236233 TMD8_NT_cl.3 TMD8_NT_cl
- GSM9236234 LY10_AID_cl.4 LY10_AID_cl
- GSM9236235 LY10_AID_cl.5 LY10_AID_cl
- GSM9236236 LY10_AID_cl.6 LY10_AID_cl
- GSM9236237 LY10_NT_cl.1 LY10_NT_cl
- GSM9236238 LY10_NT_cl.2 LY10_NT_cl
- GSM9236239 LY10_NT_cl.3 LY10_NT_cl
- GSM9236240 HBL1_4.A_AID-ER
- GSM9236241 HBL1_5.A_AID-ER
- GSM9236242 HBL1_6.A_AID-ER
- GSM9236243 HBL1_4.N_NGFR
- GSM9236244 HBL1_5.N_NGFR
- GSM9236245 HBL1_6.N_NGFR
- GSM9236246 TMD8_4.A_AID-ER
- GSM9236247 TMD8_5.A_AID-ER
- GSM9236248 TMD8_6.A_AID-ER
- GSM9236249 TMD8_4.N_NGFR
- GSM9236250 TMD8_5.N_NGFR
- GSM9236251 TMD8_6.N_NGFR
- GSM9236252 SUDHL6_AID-ER_1 SUDHL6_AID-E
- GSM9236253 SUDHL6_AID-ER_2 SUDHL6_AID-E
- GSM9236254 SUDHL6_AID-ER_3 SUDHL6_AID-E
- GSM9236255 SUDHL6_NGFR_1 SUDHL6_NGF
- GSM9236256 SUDHL6_NGFR_2 SUDHL6_NGF
- GSM9236257 SUDHL6_NGFR_3 SUDHL6_NGF
- GSM9236258 LY18_AID-ER_1 LY18_AID-E
- GSM9236259 LY18_AID-ER_2 LY18_AID-E
- GSM9236260 LY18_AID-ER_3 LY18_AID-E
- GSM9236261 LY18_NGFR_1 LY18_NGF
+ 2 more — browse all 42 samples with per-sample file links →
- GSE230396 Selective Enhancer Dependencies in MYC-Intact and MYC-Rearranged Germinal Center B-cell Diffuse Large B-cell Lymphoma 132 samples same disease briefing · shares myc, lymphoma
- GSE252690 Increased CCL2/CCR2 axis in MYC/BCL2 double-expressor DLBCL promotes tumor progression by increasing M2 macrophages 28 samples same disease briefing · shares myc
- GSE211451 Targeting AURKA to induce synthetic lethality in CREBBP-deficient DLBCL via attenuation of MYC expression 8 samples same disease briefing · shares myc
- GSE193566 Longitudinal gene expression profiling identifies a poor risk subset of patients with ABC-type Diffuse Large B Cell Lymphoma 76 samples same disease briefing · shares lymphoma
- GSE262621 Gene expression profiling of HIV-associated diffuse large B-cell lymphomas from Malawi 70 samples same disease briefing · shares lymphoma
- GSE277575 Large B-cell lymphoma imprints a dysfunctional immune phenotype that persists years after treatment 62 samples same disease briefing · shares lymphoma
- GSE267097 Pre-Treatment peripheral Immune composition can accurately predict CAR-T outcomes in patients with Large B-Cell Lymphoma 49 samples same disease briefing · shares lymphoma
- GSE213555 Molecular and pathological characterisation of diffuse large B-cell lymphomas in children with Nijmegen breakage syndrome 41 samples same disease briefing · shares lymphoma
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.